Project Details
Description
MT2022-60: A phase II study of Pembrolizumab+ BEAM conditioning regimen before autologous stem cell transplant (ASCT) followed by pembrolizumab maintenance in patients of relapsed classic Hodgkin lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 4/9/24 → 4/30/34 |
Funding
- MERCK AND CO INC
- MERCK
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.